Overview
- The European Patent Office issued a Rule 71(3) notice stating its intent to grant a patent that Silo licenses exclusively from Columbia University.
- The allowed claims cover using serotonin 4, or 5‑HT4, receptor agonists to prevent stress‑induced fear and depressive‑like behavior.
- A Rule 71(3) notice is not a final grant, and enforceable rights begin only after formal issuance and required European country actions.
- Silo said it is evaluating a Unitary Patent and key national validations to maximize coverage across Europe.
- Following the announcement, Silo Pharma’s shares rose about 47.5% in after‑hours trading.